Structure via PubChem · Public domain (PubChem)
pembrolizumab
Sign in to saveAlso known as MK-3475, lambrolizumab, Keytruda
Pembrolizumab, sold under the brand name Keytruda, is a humanized monoclonal antibody, more specifically a PD-1 inhibitor, used in cancer immunotherapy to treat many types of cancer. It is administered by slow intravenous injection.
Key facts
- Drug.type
- mab
- Drug.image
- Pembrolizumab 5DK3.png
- Drug.caption
- From PDB entry
- Drug.mab_type
- mab
- Drug.source
- zu/o
- Drug.target
- PD-1
- Drug.tradename
- Keytruda
- Drug.MedlinePlus
- a614048
- Drug.DailyMedID
- Pembrolizumab
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- Intravenous
- Drug.class
- Antineoplastic
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- FF02
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_CA_comment
- /Schedule D
- Drug.legal_UK
- POM
via Wikipedia infobox
Research
14,214 papers- Pembrolizumab (Keytruda).Human vaccines & immunotherapeutics · 2016
- Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522.Annals of oncology : official journal of the European Society for Medical Oncology · 2024
- Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
- Pembrolizumab versus Ipilimumab in Advanced Melanoma.The New England journal of medicine · 2015
- Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study.Annals of oncology : official journal of the European Society for Medical Oncology · 2025
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 149000
- Has use
- medication
Show 5 more facts
- subject has role
- monoclonal antibody
- World Health Organisation international non-proprietary name
- pembrolizumab
- route of administration
- intravenous infusion and defusion
- has characteristic
- biopharmaceutical
- physically interacts with
- programmed cell death 1
Sources (6)
via Wikidata · CC0
~29 min read
Encyclopedic overview
12 sectionsContents
- Medical uses
- Adverse effects
- Mechanism of action
- Pharmacology
- Chemistry and manufacturing
- History
- Society and culture
- Economics
- Research
- References
- Further reading
- External links
Pembrolizumab, sold under the brand name Keytruda, is a humanized monoclonal antibody, more specifically a PD-1 inhibitor, used in cancer immunotherapy to treat many types of cancer. It is administered by slow intravenous injection.
Common side effects include fatigue, musculoskeletal pain, decreased appetite, itchy skin, diarrhea, nausea, rash, fever, cough, difficulty breathing, constipation, pain, and abdominal pain. It is an IgG4 isotype antibody that blocks a protective mechanism of cancer cells, allowing the immune system to destroy them. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes.
Excerpted from Wikipedia’s “pembrolizumab” article, available under the CC BY-SA 4.0 licence.